VANLID 250 is the India's First vancomycin I.V., having strength of 250 mg for the pediatric patients. VANLID 250 is the chromatographically preserved and purified product.
S. aureus (Staphylococcus aureus) is very important pathogen, which often causes the clinical disease in the children. A wide range of illnesses may be sourced by this pathogen including non-aggressive skin infections and some life-threatening infections. In addition, the antibacterial are used to eliminate the S. aureus, it has formulated the resistance of all these significant therapeutic agents. Growing the bacterial resistance means they were effective once and the inexpensive treatments for the infections sourced by these pathogens are being seriously questioned now.
MRSA (Methicillin Resistant S. Aureus) has turn into a rising problem in the pediatric patients in the last decade. A new kind of staphylococcus, normally termed as CA-MRSA (Community-Acquired MRSA) that is tolerable to the fewer antibiotics compared with HA-MRSA, has emerged in pediatric age group also.
In the year 1958, the Vancomycin was introduced. Since then, it has been very useful antibiotic for around 50 years. The modern advent of the MRSA has given a rebirth to this glycopeptides. In last few years, vancomycin has become the main supporter of the MRSA infection therapy. It is a primary therapeutic alternative in severe and life-threatening MRSA infections.
A lot of literature shows vancomycin, as clinically as well as micro-biologically (including resistant Gram-positive organisms), very effective against all the infections caused by the documented or presumed immune Gram-positive pathogens in all the pediatric age-groups, including the neonates. Vancomycin is very safe and well-tolerated in the pediatric patients including critically ill neonates.
VANLID 250 is the India's First vancomycin I.V., having strength of 250 mg for the pediatric patients. VANLID 250 is the chromatographically preserved and purified product. VANLID 250 is used for treatment against the staphylococcal infections like septicaemia, lower RTI (Respiratory Tract Infections) pneumonia for instance, osteomyelitis, and skin & soft-tissue infections. It is also used for the treatment of endocarditis, which is caused by the Staphylococci, Diphtheroids, Streptococcus viridans*/Streptococcus bovis*, or the Enterococci (for instance E. faecalis )**, for treatment of early-oncoming prosthetic valve endocarditis, sourced by the Staphylococcus epidermidis/diphtheroids $ with as prophylaxis against the endocarditis in the patients, having risk of surgical or dental procedures.
In the pediatric patients, the normal I.V. dose of 10 mg/kg is suggested every 6 hours (whole daily dose of 40 mg/kg of the body weight). In young infants and neonates, the first dose having 15 mg/kg is recommended, followed by the 10 mg/kg in every 12 hours within first week of the life as well as every 8 hours subsequently until the age of 1 month. Longer dosing intervals can be required in the premature infants. Every dose must be administered over the period of minimum 60 minutes. Parenteral form of the vancomcin may be given orally for the treatment of antibiotic-related pseudo membranous colitis, originated by Staphylococcal enterocolitis and C. difficile.
Orally, the VANLID 250 I.V. may be administered using the 40 mg/kg of body weight in three/four divided doses, given for 7 to 10 days. The total day-to-day dose must not exceed 2 g.
Dosage adjustment has to be made in the patients, having impaired renal function.
*Vancomycin only or in combination with the amino glycoside
**Vancomycin only in composition with the amino glycoside
$ Vancomycin in composition with either amino glycoside or rifampin or both
Content Source: Source: http://www.cipla.com/whatsnew/products.htm
Image Source: Morguefile dot com